Compare Main Street Capital Corporation (MAIN) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Medpace Holdings Inc — how do they compare? Main Street Capital Corporation trades at $58.73 (market cap $5.52B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 3.1× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays a 5.39% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MAIN | MEDP | |
|---|---|---|
Market Cap | $5.52B | $16.90B |
Sector | Financials | Technology |
52-Week High | $67.54 | $620.59 |
52-Week Low | $49.63 | $393.42 |
Dividend Yield | 5.39% | — |
Enterprise Value | — | $16.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $58.51, slightly below the consensus price target of $56.67, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company maintains strong profitability with an 80.77% net income margin and 14.92% ROE, though Q2 2026 earnings of $0.97 per share missed expectations. Recent dividend announcements and portfolio appreciation highlight MAIN's income-focused strategy in the BDC sector.
MAIN presents a stable income opportunity with consistent dividends, but faces headwinds from higher expenses impacting recent earnings. The stock's current valuation at 11.85x P/E appears reasonable, though investor caution is warranted given the majority hold rating from analysts and competitive pressures in the private credit market.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
